Temeng Kwaku 4

What Happened Temeng Kwaku, a director of Core Laboratories, had a conversion/exercise of derivative awards and a new restricted share grant on April 1, 2026. The filing reports an acquisition (conversion) of 8,069 shares at $0.00 and an immediate disposition of the same 8,069 shares at $0.00. In addition, Kwaku was reported as acquiring 7,895 restricted shares (derivative) at $0.00. The filing shows $0 consideration for these items as reported on the Form 4.

Key Details

• Transaction date: April 1, 2026.
• Reported transactions:
  • Exercise/conversion (code M) — 8,069 shares acquired @ $0.00 (reported value $0).
  • Grant/award (code A, derivative) — 7,895 restricted shares acquired @ $0.00 (reported value $0).
  • Exercise/conversion (code M) — 8,069 shares disposed @ $0.00 (reported value $0).
• Shares owned after transaction: Not disclosed in the excerpt provided.
• Footnotes:
  • F2: The Restricted Shares referenced vested at the end of a one‑year vesting period ending April 1, 2026.
  • F1: The 7,895 Restricted Shares will vest (without performance criteria) on April 1, 2027 and are subject to a deferral election and distribution rules per Treasury Reg. 1.409A‑2.
• Filing timeliness: Form filed April 7, 2026 for April 1 transactions — this is several days after the trades and appears later than the typical two-business-day Form 4 deadline.

Context

• The filing shows a conversion/vesting event and a near‑immediate disposition of the same number of shares — a pattern commonly associated with sell‑to‑cover or tax withholding when RSUs vest (footnote F2 confirms vesting). The new 7,895 restricted shares are subject to a one‑year vesting schedule (footnote F1).
• These are director equity compensation transactions (not a 10% owner or open‑market purchase/sale by an officer). Such routine compensation-related conversions and withholdings are common and do not by themselves indicate the director’s view of the company.